Mice Lacking Both Presenilin Genes Exhibit Early Embryonic Patterning Defects
Total Page:16
File Type:pdf, Size:1020Kb

Load more
Recommended publications
-
Spatial Regulation and Generation of Diversity in Signaling Pathways
J Biosci (2021)46:30 Ó Indian Academy of Sciences DOI: 10.1007/s12038-021-00150-w (0123456789().,-volV)(0123456789().,-volV) Review Spatial regulation and generation of diversity in signaling pathways 1,2 1 NEETU SAINI and APURVA SARIN * 1Institute for Stem Cell Science and Regenerative Medicine, Bellary Road, Bengaluru 560 065, India 2Department of Biology, Manipal Academy of Higher Education, Manipal, India *Corresponding author (Email, [email protected]) MS received 9 November 2020; accepted 19 February 2021 Signaling pathways orchestrate diverse cellular outcomes in the same tissue, spatially and temporally. These interactions, which are played out in micro-environments within cells and involve a relatively small number of core pathways, are the key to the development and function of multi-cellular organisms. How these outcomes are regulated has prompted interest in intracellular mechanisms that build diversity in signaling outcomes. This review specifically addresses spatial positioning of molecules as a means of enabling interactions and novel outcomes of signaling cascades. Using the Notch and Ras pathways as exemplars, we describe mechanisms that contribute to diverse signaling outcomes. Keywords. Cross-talk; notch; signaling; spatial regulation 1. Introduction and Blair 1999; Baonza and Garcia-Bellido 2000; Becam et al. 2011), and in the lymph gland, the dif- Cell-to-cell communication is critical for the develop- ferentiation and survival of crystal cells (Duvic et al. ment and maintenance of multi-cellular organisms. 2002). In the PC12 neuronal cell line, activation of Development or repair following injury, requires receptor tyrosine kinase (RTK) in response to nerve interactions between many cell types for specific of cell growth factor (NGF) and epidermal growth factor fates, and breakdown or errors in these can lead to (EGF) regulates differentiation and proliferation various disorders or pathophysiological conditions respectively. -
Tyrosine Phosphorylation and Proteolytic Cleavage of Notch Are
© 2018. Published by The Company of Biologists Ltd | Development (2018) 145, dev151548. doi:10.1242/dev.151548 RESEARCH ARTICLE Tyrosine phosphorylation and proteolytic cleavage of Notch are required for non-canonical Notch/Abl signaling in Drosophila axon guidance Ramakrishnan Kannan1,*, Eric Cox1,‡, Lei Wang2,§, Irina Kuzina1,QunGu1 and Edward Giniger1,2,¶ ABSTRACT 2005) and the Akt pathway (Androutsellis-Theotokis et al., 2006; Notch signaling is required for the development and physiology of Perumalsamy et al., 2009), among others, that extend the menu of nearly every tissue in metazoans. Much of Notch signaling is molecular outcomes of Notch activation. The molecular events mediated by transcriptional regulation of downstream target genes, behind these alternative signaling mechanisms, however, are not well but Notch controls axon patterning in Drosophila by local modulation understood. of Abl tyrosine kinase signaling, via direct interactions with the Abl co- Perhaps the best-studied non-traditional function of Notch is its factors Disabled and Trio. Here, we show that Notch-Abl axonal regulation of axon patterning (comprising both axon growth and signaling requires both of the proteolytic cleavage events that initiate axon guidance) via interaction with the Abl tyrosine kinase canonical Notch signaling. We further show that some Notch protein signaling network (Crowner et al., 2003; Giniger, 1998; Kuzina is tyrosine phosphorylated in Drosophila, that this form of the protein et al., 2011; Le Gall et al., 2008). It has been demonstrated is selectively associated with Disabled and Trio, and that relevant biochemically, molecularly and genetically that, upon activation by tyrosines are essential for Notch-dependent axon patterning but not its ligand Delta, Notch promotes the growth and guidance of pioneer for canonical Notch-dependent regulation of cell fate. -
343747488.Pdf
Washington University School of Medicine Digital Commons@Becker Open Access Publications 6-1-2020 Systematic validation of variants of unknown significance in APP, PSEN1 and PSEN2 Simon Hsu Anna A Pimenova Kimberly Hayes Juan A Villa Matthew J Rosene See next page for additional authors Follow this and additional works at: https://digitalcommons.wustl.edu/open_access_pubs Authors Simon Hsu, Anna A Pimenova, Kimberly Hayes, Juan A Villa, Matthew J Rosene, Madhavi Jere, Alison M Goate, and Celeste M Karch Neurobiology of Disease 139 (2020) 104817 Contents lists available at ScienceDirect Neurobiology of Disease journal homepage: www.elsevier.com/locate/ynbdi Systematic validation of variants of unknown significance in APP, PSEN1 T and PSEN2 Simon Hsua, Anna A. Pimenovab, Kimberly Hayesa, Juan A. Villaa, Matthew J. Rosenea, ⁎ Madhavi Jerea, Alison M. Goateb, Celeste M. Karcha, a Department of Psychiatry, Washington University School of Medicine, 425 S Euclid Avenue, St Louis, MO 63110, USA b Department of Neuroscience, Mount Sinai School of Medicine, New York, NY, USA ARTICLE INFO ABSTRACT Keywords: Alzheimer's disease (AD) is a neurodegenerative disease that is clinically characterized by progressive cognitive APP decline. More than 200 pathogenic mutations have been identified in amyloid-β precursor protein (APP), presenilin PSEN1 1 (PSEN1) and presenilin 2 (PSEN2). Additionally, common and rare variants occur within APP, PSEN1, and PSEN2 PSEN2 that may be risk factors, protective factors, or benign, non-pathogenic polymorphisms. Yet, to date, no Alzheimer's disease single study has carefully examined the effect of all of the variants of unknown significance reported in APP, Cell-based assays PSEN1 and PSEN2 on Aβ isoform levels in vitro. -
It's T-ALL About Notch
Oncogene (2008) 27, 5082–5091 & 2008 Macmillan Publishers Limited All rights reserved 0950-9232/08 $30.00 www.nature.com/onc REVIEW It’s T-ALL about Notch RM Demarest1, F Ratti1 and AJ Capobianco Molecular and Cellular Oncogenesis, The Wistar Institute, Philadelphia, PA, USA T-cell acute lymphoblastic leukemia (T-ALL) is an about T-ALL make it a more aggressive disease with a aggressive subset ofALL with poor clinical outcome poorer clinical outcome than B-ALL. T-ALL patients compared to B-ALL. Therefore, to improve treatment, it have a higher percentage of induction failure, and rate is imperative to delineate the molecular blueprint ofthis of relapse and invasion into the central nervous system disease. This review describes the central role that the (reviewed in Aifantis et al., 2008). The challenge to Notch pathway plays in T-ALL development. We also acquiring 100% remission in T-ALL treatment is the discuss the interactions between Notch and the tumor subset of patients (20–25%) whose disease is refractory suppressors Ikaros and p53. Loss ofIkaros, a direct to initial treatments or relapses after a short remission repressor ofNotch target genes, and suppression ofp53- period due to drug resistance. Therefore, it is imperative mediated apoptosis are essential for development of this to delineate the molecular blueprint that collectively neoplasm. In addition to the activating mutations of accounts for the variety of subtypes in T-ALL. This will Notch previously described, this review will outline allow for the development of targeted therapies that combinations ofmutations in pathways that contribute inhibit T-ALL growth by disrupting the critical path- to Notch signaling and appear to drive T-ALL develop- ways responsible for the neoplasm. -
Genetic Testing for Familial Alzheimer's Disease
Corporate Medical Policy Genetic Testing for Familial Alzheimer’s Disease AHS – M2038 File Name: genetic_testing_for_familial_alzheimers_disease Origination: 1/2019 Last CAP Review: 10/2020 Next CAP Review: 10/2021 Last Review: 10/2020 Description of Procedure or Service Alzheimer disease (AD) is a neurodegenerative disease defined by a gradual decline in memory, cognitive functions, gross atrophy of the brain, and an accumulation of extracellular amyloid plaques and intracellular neurofibrillary tangles (Karch, Cruchaga, & Goate, 2014). Familial Alzheimer disease (FAD) is a rare, inherited form of AD. FAD has a much earlier onset than other forms of Alzheimer disease with symptoms developing in individuals in their thirties or forties. Related Policies General Genetic Testing, Germline Disorders AHS – M2145 General Genetic Testing, Somatic Disorders AHS – M2146 ***Note: This Medical Policy is complex and technical. For questions concerning the technical language and/or specific clinical indications for its use, please consult your physician. Policy BCBSNC will provide coverage for genetic testing for familial Alzheimer disease when it is determined the medical criteria or reimbursement guidelines below are met. Benefits Application This medical policy relates only to the services or supplies described herein. Please refer to the Member's Benefit Booklet for availability of benefits. Member's benefits may vary according to benefit design; therefore member benefit language should be reviewed before applying the terms of this medical policy. -
Membrane Topology of the C. Elegans SEL-12 Presenilin
Neuron, Vol. 17, 1015±1021, November, 1996, Copyright 1996 by Cell Press Membrane Topology of the C. elegans SEL-12 Presenilin Xiajun Li* and Iva Greenwald*²³ [this issue of Neuron]; Thinakaran et al., 1996). In the *Integrated Program in Cellular, Molecular, Discussion, we examine the amino acid sequence in and Biophysical Studies light of the deduced topology. ² Department of Biochemistry and Molecular Biophysics Results ³ Howard Hughes Medical Institute Columbia University Sequence analysis suggests that SEL-12 and human College of Physicians and Surgeons presenilins have ten hydrophobic regions (Figure 1). In New York, New York 10032 this study, we provide evidence that a total of eight of these hydrophobic regions function as transmembrane domains in vivo. Below, we use the term ªhydrophobic Summary regionº to designate a segment of the protein with the potential to span the membrane, as inferred by hydro- Mutant presenilins cause Alzheimer's disease. Pre- phobicity analysis, and ªtransmembrane domainº to senilins have multiple hydrophobic regions that could designate a hydrophobic region that our data suggest theoretically span a membrane, and a knowledge of actually spans a membrane. the membrane topology is crucial for deducing the mechanism of presenilin function. By analyzing the activity of b-galactosidase hybrid proteins expressed Strategy in C. elegans, we show that the C. elegans SEL-12 We constructed transgenes encoding hybrid SEL- presenilin has eight transmembrane domains and that 12::LacZ proteins, in which LacZ was placed after each there is a cleavage site after the sixth transmembrane of ten hydrophobic regions identified by hydrophobicity domain. We examine the presenilin sequence in view analysis (see Figure 1). -
Suppression of Notch Signaling Stimulates Progesterone Synthesis by Enhancing the Expression of NR5A2 and NR2F2 in Porcine Granulosa Cells
G C A T T A C G G C A T genes Article Suppression of Notch Signaling Stimulates Progesterone Synthesis by Enhancing the Expression of NR5A2 and NR2F2 in Porcine Granulosa Cells Rihong Guo 1,2, Fang Chen 2 and Zhendan Shi 1,2,* 1 Jiangsu Key Laboratory for Food Quality and Safety-State Key Laboratory Cultivation Base of Ministry of Science and Technology, Jiangsu Academy of Agricultural Sciences, Nanjing 210014, China; [email protected] 2 Institute of Animal Science, Jiangsu Academy of Agricultural Sciences, Nanjing 210014, China; [email protected] * Correspondence: [email protected] Received: 16 December 2019; Accepted: 18 January 2020; Published: 22 January 2020 Abstract: The conserved Notch pathway is reported to be involved in progesterone synthesis and secretion; however, the exact effects remain controversial. To determine the role and potential mechanisms of the Notch signaling pathway in progesterone biosynthesis in porcine granulosa cells (pGCs), we first used a pharmacological γ-secretase inhibitor, N-(N-(3,5-difluorophenacetyl-l-alanyl))-S-phenylglycine t-butyl ester (DAPT), to block the Notch pathway in cultured pGCs and then evaluated the expression of genes in the progesterone biosynthesis pathway and key transcription factors (TFs) regulating steroidogenesis. We found that DAPT dose- and time-dependently increased progesterone secretion. The expression of steroidogenic proteins NPC1 and StAR and two TFs, NR5A2 and NR2F2, was significantly upregulated, while the expression of HSD3B was significantly downregulated. Furthermore, knockdown of both NR5A2 and NR2F2 with specific siRNAs blocked the upregulatory effects of DAPT on progesterone secretion and reversed the effects of DAPT on the expression of NPC1, StAR, and HSD3B. -
Cerebrospinal Fluid Biomarkers for Differentiating Between Alzheimer‟S Disease and Vascular Dementia
Cerebrospinal fluid biomarkers for differentiating between Alzheimer‟s disease and Vascular dementia Maria Bjerke Institute of Neuroscience and Physiology Department of Psychiatry and Neurochemistry The Sahlgrenska Academy Gothenburg University 2011 ISBN 978-91-628-8312-6 © Maria Bjerke Institute of Neuroscience and Physiology Gothenburg University Sweden Printed at Intellecta Infolog Gothenburg Sweden, 2011 To my family ABSTRACT Patients suffering from mild cognitive impairment (MCI) run a higher risk of developing dementia, with Alzheimer‟s disease (AD) being the most common form. Vascular dementia (VaD) is proposed to be the second most common dementia entity, and it includes the clinically relatively homogenous subgroup of subcortical vascular dementia (SVD). Varying degrees of concomitant vascular lesions represent a link between AD and VaD, comprising a state of mixed dementia (MD). Biochemical markers provide important information which may contribute to differentiating between dementias of different etiologies, and in combination with the clinical assessment may improve diagnostic accuracy. The overall aim of this thesis is to provide for better separation between patients suffering from SVD and AD with the aid of biochemical markers. The cerebrospinal fluid (CSF) biomarkers T-tau, P-tau181, and Aβ1-42, have proven useful in distinguishing MCI patients who ultimately develop AD (MCI-AD) at follow-up from those who remain stable. However, less is known about the biomarker pattern in MCI patients who develop SVD (MCI-SVD). An elevated baseline level of NF-L was found in MCI-SVD patients compared with stable MCI patients, while MCI-AD had decreased levels of Aβ1-42 and increased levels of T- tau and P-tau181 compared with MCI-SVD patients and stable MCI patients. -
Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes
Tohoku J. Exp. Med., 2011,Differential 223, 161-176 Gene Expression in OPCs, Oligodendrocytes and Type II Astrocytes 161 Differential Gene Expression in Oligodendrocyte Progenitor Cells, Oligodendrocytes and Type II Astrocytes Jian-Guo Hu,1,2,* Yan-Xia Wang,3,* Jian-Sheng Zhou,2 Chang-Jie Chen,4 Feng-Chao Wang,1 Xing-Wu Li1 and He-Zuo Lü1,2 1Department of Clinical Laboratory Science, The First Affiliated Hospital of Bengbu Medical College, Bengbu, P.R. China 2Anhui Key Laboratory of Tissue Transplantation, Bengbu Medical College, Bengbu, P.R. China 3Department of Neurobiology, Shanghai Jiaotong University School of Medicine, Shanghai, P.R. China 4Department of Laboratory Medicine, Bengbu Medical College, Bengbu, P.R. China Oligodendrocyte precursor cells (OPCs) are bipotential progenitor cells that can differentiate into myelin-forming oligodendrocytes or functionally undetermined type II astrocytes. Transplantation of OPCs is an attractive therapy for demyelinating diseases. However, due to their bipotential differentiation potential, the majority of OPCs differentiate into astrocytes at transplanted sites. It is therefore important to understand the molecular mechanisms that regulate the transition from OPCs to oligodendrocytes or astrocytes. In this study, we isolated OPCs from the spinal cords of rat embryos (16 days old) and induced them to differentiate into oligodendrocytes or type II astrocytes in the absence or presence of 10% fetal bovine serum, respectively. RNAs were extracted from each cell population and hybridized to GeneChip with 28,700 rat genes. Using the criterion of fold change > 4 in the expression level, we identified 83 genes that were up-regulated and 89 genes that were down-regulated in oligodendrocytes, and 92 genes that were up-regulated and 86 that were down-regulated in type II astrocytes compared with OPCs. -
1 Presenilin-Based Genetic Screens in Drosophila Melanogaster Identify
Genetics: Published Articles Ahead of Print, published on January 16, 2006 as 10.1534/genetics.104.035170 Presenilin-based genetic screens in Drosophila melanogaster identify novel Notch pathway modifiers Matt B. Mahoney*1, Annette L. Parks*2, David A. Ruddy*3, Stanley Y. K. Tiong*, Hanife Esengil4, Alexander C. Phan5, Panos Philandrinos6, Christopher G. Winter7, Kari Huppert8, William W. Fisher9, Lynn L’Archeveque10, Felipa A. Mapa11, Wendy Woo, Michael C. Ellis12, Daniel Curtis11 Exelixis, Inc., South San Francisco, California, 94083 Present addresses: 1Department of Discovery, EnVivo Pharmaceuticals, Watertown, Massachusetts, 02472 2Biology Department, Boston College, Chestnut Hill, Massachusetts, 02467 3Oncology Targets and Biomarkers, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts, 02139 4Department of Molecular Pharmacology, Stanford University, Stanford, California, 94305 5Department of Biostatistics, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland, 21205 6ITHAKA Academic Cultural Program in Greece, San Francisco, California, 94102 7Merck Research Laboratories, Boston, Massachusetts, 02115 8Donald Danforth Plant Science Center, St. Louis, Missouri, 63132 1 9Life Sciences Division, Lawrence Berkeley National Laboratory, Berkeley, California, 94720 10Biocompare, Inc., South San Francisco, California, 94080 11Developmental and Molecular Pathways, Novartis Institutes for BioMedical Research, Inc., Cambridge, Massachusetts, 02139 12Renovis, Inc., South San Francisco, California, 94080 -
The Use of Antimicrobial and Antiviral Drugs in Alzheimer's Disease
International Journal of Molecular Sciences Review The Use of Antimicrobial and Antiviral Drugs in Alzheimer’s Disease Umar H. Iqbal, Emma Zeng and Giulio M. Pasinetti * Department of Neurology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA; [email protected] (U.H.I.); [email protected] (E.Z.) * Correspondence: [email protected]; Tel.: +1-212-241-7938 Received: 29 May 2020; Accepted: 10 July 2020; Published: 12 July 2020 Abstract: The aggregation and accumulation of amyloid-β plaques and tau proteins in the brain have been central characteristics in the pathophysiology of Alzheimer’s disease (AD), making them the focus of most of the research exploring potential therapeutics for this neurodegenerative disease. With success in interventions aimed at depleting amyloid-β peptides being limited at best, a greater understanding of the physiological role of amyloid-β peptides is needed. The development of amyloid-β plaques has been determined to occur 10–20 years prior to AD symptom manifestation, hence earlier interventions might be necessary to address presymptomatic AD. Furthermore, recent studies have suggested that amyloid-β peptides may play a role in innate immunity as an antimicrobial peptide. These findings, coupled with the evidence of pathogens such as viruses and bacteria in AD brains, suggests that the buildup of amyloid-β plaques could be a response to the presence of viruses and bacteria. This has led to the foundation of the antimicrobial hypothesis for AD. The present review will highlight the current understanding of amyloid-β, and the role of bacteria and viruses in AD, and will also explore the therapeutic potential of antimicrobial and antiviral drugs in Alzheimer’s disease. -
“The Use of CRISPR Technology to Test Gene Therapy As a Treatment
The Dana Foundation’s “Design a Brain Experiment” Competition 2017 First Place “The Use of CRISPR Technology to Test Gene Therapy as a Treatment to Early-Onset Familial Alzheimer’s Disease in Zebrafish” By Medha Palnati Westford Academy, Massachusetts Lay Summary (provided by the Dana Foundation): Early- onset Familial Alzheimer’s disease (FAD), which occurs in about five percent of all people with AD, develop the disease sometime between age 30 and 60. Usually FAD is caused by an inherited mutation in one of three genes. An infant born to a parent who carries the genetic mutation has a 50 percent chance of inheriting that mutation; an infant that inherits it has a strong likelihood of developing early-onset FAD. Any of several different single gene mutations on chromosomes 21, 14, and 1 causes abnormal protein formation. A mutation on chromosome 21 results in formation of abnormal amyloid precursor protein (APP), while a mutation on chromosome 14 or 1 produces abnormal presenilin 1 or presenilin 2, respectively. Each contributes to APP breakdown, generating accumulation of harmful amyloid plaques between brain cells that eventually disrupt communication from one cell to another. Medha’s experiment explores the potential of using an exciting new experimental form of gene therapy to treat FAD. To test this potential therapy, she uses the transgenic zebrafish model which has “ortholog” genes psen1, psen2, and appa and appb that can be individually manipulated using this experimental gene therapy called CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats). CRISPR is a unique technology for editing parts of the genome by removing, adding, or altering sections of the DNA sequence.